Amlodipine/valsartan single-pill combination: A review of its use in the management of hypertension

American Journal of Cardiovascular Drugs

Volumn 9, Issue 5, 2009, Pages 309-330

  Frampton, James E ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS VALSARTAN; ATENOLOL; CIMETIDINE; DIGOXIN; FUROSEMIDE; GLIBENCLAMIDE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; INDOMETACIN; PLACEBO; VALSARTAN; WARFARIN;

ADD ON THERAPY; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMPARATIVE STUDY; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; LOW BACK PAIN; MONOTHERAPY; NEPHROTIC SYNDROME; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PHARYNGITIS; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SHORT COURSE THERAPY; SINUSITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

ADULT; AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; TETRAZOLES; VALINE;

EID: 70349748258     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11201120-000000000-00000     Document Type: Review

References (67)

1. He J, Whelton PK. Epidemiology and prevention of hypertension. Med Clin North Am 1997 Sep; 81 (5): 1077-1097
2. Ong KL, Cheung BMY, Man YB. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007; 49: 69-75
3. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42 (6): 1206-1252
4. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007 May 29; 115 (21): 2761-2788
5. Chrysant SG. Using fixed-dose combination therapies to achieve blood pressure goals. Clin Drug Invest 2008; 28 (11): 713-734
6. Neutel JM. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients. Curr Med Res Opin 2008 Aug; 24 (8): 2389-2401
7. Calhoun DA. Use of single-pill combination therapy in evolving paradigm of hypertension management. Expert Opin Pharmacother 2009 Aug; 10 (12): 1869-1874
8. Waeber B, Ruilope LM. Amlodipine and valsartan as components of a rational and effective fixed-dose combination. Vasc Health Risk Manag 2009; 5 (1): 165-174
9. Ram CVS. Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: a review of factorial design studies. Curr Med Res Opin 2009; 25 (1): 177-185
10. Bakris GL. Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens (Greenwich) 2008 Jan; 10 (1 Suppl. 1): 27-32
11. Gojanovic B, Feihl F, Liaudet L, et al. Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension. J Renin Angiotensin Aldosterone Syst 2008 Mar; 9 (1): 1-9 (Pubitemid 351546627)
12. Ferri C, Croce G, Desideri G. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine. Adv Ther 2008 Apr; 25 (4): 300-320
13. de la Sierra A. Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system. J Hum Hypertens 2009 Aug; 23 (8): 503-511
14. Exforge® (amlodipine and valsartan) tablets: US prescribing information. East Hanover (NJ): Novartis Pharmaceuticals Corp., 2008 Jul
15. Azor® (amlodipine and olmesartan medoxomil) tablets. US prescribing information. Parsippany (NJ): Daiichi Sankyo Inc., 2007
16. Haria M, Wagstaff AJ. Amlodipine: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995; 50 (3): 560-586
17. Plosker GL, Robinson DM. Amlodipine/valsartan: fixed-dose combination in hypertension. Drugs 2008; 68 (3): 373-381
18. Markham A, Goa KL. Valsartan: a review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997 Aug; 54 (2): 299-311 (Pubitemid 27361837)
19. Norvasc (amlodipine besylate) tablets. US prescribing information. New York: Pfizer Inc., 2006 Aug
20. Diovan (valsartan) tablets. US prescribing information. East Hanover (NJ): Novartis Pharmaceuticals Corp., 2008 Dec
21. Top C, Cingö zbay BY, Terekeci H, et al. The effects of valsartan on insulin sensitivity in patients with primary hypertension. J Int Med Res 2002; 30 (1): 15-20
22. Ram CVS, Ames RP, Applegate WB, et al. Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension. Clin Cardiol 1994; 17: 251-256 (Pubitemid 24138649)
23. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004; 64 (22): 2537-2565 (Pubitemid 39591650)
24. Fogari R, Derosa G, Lazzari P, et al. Effect of valsartan-amlodipine combination on inflammation markers, oxidative stress and on assymetric dimethylarginine in type 2 diabetic hypertensive patients [abstract no. PS12/MON/05]. J Hypertens 2008; 26 Suppl. 1: 188
25. Fogari R, Zoppi A, Mugellini A, et al. Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. J Cardiovasc Pharmacol 2008 Mar; 51 (3): 217-222
26. Fogari R, Preti P, Zoppi A, et al. Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients. Intern Med 2008; 47 (21): 1851-1857
27. Fogari R, Derosa G, Lazzari P, et al. Effect of valsartan-amlodipine combination on cognitive function in elderly hypertensive patients [abstract no. PS26/WED/06]. J Hypertens 2008; 26 Suppl. 1: 372
28. Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007 Mar; 21 (3): 220-224 (Pubitemid 46267738)
29. de Champlain J, Karas M, Assouline L, et al. Effects of valsartan or amlodipine alone or in combination on plasma catecholamine levels at rest and during standing in hypertensive patients. J Clin Hypertens 2007 Mar; 9 (3): 168-178
30. Exforge 5mg/80 mg, 5 mg/160 mg, 10mg/160mg film coated tablets: summary of product characteristics. Camberley, UK: Novartis Pharmaceuticals UK Ltd, 2008 Jun 10
31. European Medicines Agency. Exforge European public assessment report: scientific discussion [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/exforge/H-716-en6.pdf [Accessed 2009 Mar 25]
32. Co-Diovan® valsartan and hydrochlorothiazide: Australian prescribing information. North Ryde (NSW): Novartis Pharmaceuticals Australia Pty Ltd, 2009 Feb 13
33. US Food and Drug Administration Center for Drug Evaluation and Research. Application number: 21-990 Exforge; amlodipine besylate & valsartan. Clinical Pharmacology and Biopharmaceutics Review [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2007/021990s000-ClinPharmR. pdf [Accessed 2009 Jul 16]
34. US Food and Drug Administration Center for Drug Evaluation and Research. Application number: 21-990 Exforge; amlodipine besylate & valsartan. Medical Review [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2007/ 021990s000-MedR.pdf [Accessed 2009 Mar 3]
35. Allemann Y, Fraile B, Lambert M, et al. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study. J Clin Hypertens (Greenwich) 2008 Mar; 10 (3): 185-194
36. Data on file, Novartis Pharmaceuticals Corp., 2009
37. Schrader J, Salvetti A, Calvo C, et al. The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10mg in hypertensive patients not adequately controlled with amlodipine 5mg. Int J Clin Pract 2009; 63 (2): 217-225
38. Flack JM, Calhoun DA, Satlin L, et al. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens 2009 Jul; 23 (7): 479-489
39. Destro M, Luckow A, Samson M, et al. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS Study. J Am Soc Hypertens 2008; 2 (4): 294-302
40. Sinkiewicz W, Glazer RD, Kavoliuniene A, et al. Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on valsartan monotherapy. Curr Med Res Opin 2009 Feb; 25 (2): 315-324
41. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007 Apr; 29 (4): 563-580
42. Poldermans D, Glazer R, Karagianniss S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther 2007 Feb; 29 (2): 279-289
43. Fogari R, Zoppi A, Mugellini A, et al. Efficacy and safety of two treatment combinations of hypertension in very elderly patients. Arch Gerontol Geriatr 2008 May; 48 (3): 401-405
44. Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens 2007 May; 9 (5): 355-364
45. Brachmann J, Ansari A, Mahla G, et al. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy. Adv Ther 2008 Sep; 25 (5): 399-411
46. Philipp T, Glazer RD, Zhao Y, et al. Long-term tolerability and efficacy of the combination of amlodipine/valsartan in hypertensive patients: a 54-week, open-label extension study. Curr Med Res Opin 2009; 25 (1): 187-193
47. Smith TR, Glazer R, Koren MJ, et al. Long-term safety and efficacy of combination therapy with amlodipine and valsartan in hypertensive patients [abstract P-70]. J Clin Hypertens 2008 May; 10 (5 Suppl. A): 35
48. Gu Q, Paulose-Ram R, Dillon C, et al. Antihypertensive medication use among US adults with hypertension. Circulation 2006; 113: 213-221
49. Wang RY, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med 2007; 167: 141-147 (Pubitemid 46151611)
50. Whitworth JA, World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-1992
51. ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension. J Hypertens 2007; 25: 1751-1762
52. Cooper R, Rotimi C. Hypertension in blacks. Am J Hypertens 1997 Jul; 10 (7 Pt 1): 804-812
53. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans: consensus statement of the hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003 Mar 10; 163 (5): 525-541 (Pubitemid 36314340)
54. Kohlmann Jr O, Oigman W, Mion D, et al. The "LOTHAR" study: evaluation of efficacy and tolerability of the fixed combination of amlodipine and losartan in the treatment of essential hypertension. Arq Bras Cardiol 2006 Jan; 86 (1): 39-51
55. Sharma A, Bagchi A, Kinagi SB, et al. Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension. Clin Ther 2007 Dec; 29 (12): 2667-2676
56. Leenen FHH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group. Hypertension 2006; 48: 374-384
57. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes. CAFE Investigators. Circulation 2006; 113: 1213-1225
58. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503-1510
59. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA 2004 Nov 10; 292 (18): 2217-2226
60. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multientre randomised controlled trial. Lancet 2005 Sep 10; 366 (9489): 895-906
61. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. Valsartan Heart Failure Trial (Val-HeFT) Investigators. N Engl J Med 2001 Dec 6; 345 (23): 1667-1675
62. Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the valsartan heart failure trial (Val-HeFT). Am Heart J 2005; 149: 548-557 (Pubitemid 40585420)
63. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. Valsartan in Acute Myocardial Infarction (VALIANT) Trial Investigators. N Engl J Med 2003 Nov 13; 349 (20): 1893-1906
64. Mochizuki S, Dahlöf B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007 Apr 28; 369: 1431-1439
65. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004 Jun 19; 363: 2022-2031
66. ICH Steering Committee. Guidance document: principles for evaluation of new antihypertensive drugs [online]. Available from URL: http://www.ich.org/LOB/ media/MEDIA488.pdf [Accessed 2009 Apr 29]
67. White WB. Relevance of blood pressure variation in the circadian onset of cardiovascular events. J Hypertens 2003; 21 Suppl. 6: S9-15